GLP-1 Medications Explained: What Ozempic, Wegovy, and Mounjaro Actually Do – and Who They’re Actually For

GLP-1 receptor agonists have generated more public conversation about prescription medications in the past few years than anything since statins. Ozempic, Wegovy, Mounjaro, Zepbound – these names appear in news articles, celebrity interviews, social media debates, and doctor’s office conversations in a way that’s rare for any medication class.

The enthusiasm is understandable: these are genuinely remarkable medications. The concern about their use context is also legitimate: widespread use in people who don’t medically need them creates shortages for people who do, and long-term safety data in healthy people is limited.

Understanding what these medications actually are, how they work, what they’re approved for, and what the evidence actually shows cuts through both the hype and the backlash.

What GLP-1 Receptor Agonists Are

GLP-1 (glucagon-like peptide-1) is a hormone produced by L-cells in the small intestine in response to food. It has several important physiological roles:

• Stimulates the pancreas to release insulin in response to elevated blood glucose (glucose-dependent – meaning it only drives insulin release when glucose is actually elevated, reducing hypoglycemia risk)
• Suppresses glucagon release (glucagon raises blood glucose – suppressing it lowers it)
• Slows gastric emptying (food leaves the stomach more slowly, blunting post-meal glucose spikes)
• Acts on the hypothalamus and brainstem to reduce appetite and increase satiety
• Has direct effects on cardiovascular function

Natural GLP-1 has a half-life of approximately 2 minutes – it’s rapidly broken down by the enzyme DPP-4. GLP-1 receptor agonists are engineered versions that are resistant to DPP-4 degradation, allowing them to produce sustained GLP-1 receptor activation over hours, days, or weeks.

The Key Medications – What’s What

The important distinction: Ozempic and Wegovy are the same active ingredient (semaglutide) at different approved doses. Ozempic is approved for type 2 diabetes at up to 2mg weekly. Wegovy is approved for weight management at up to 2.4mg weekly. This is why prescribing Ozempic off-label for weight loss has created a shortage of the medication for diabetic patients.

Tirzepatide (Mounjaro/Zepbound) is a dual agonist – it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism produces greater weight loss than GLP-1 agonism alone.

What They Do for Blood Sugar

In type 2 diabetes, GLP-1 receptor agonists lower HbA1c by approximately 1-1.5 percentage points for semaglutide and up to 2+ percentage points for tirzepatide – making them among the most effective glucose-lowering medications available.

Key advantages for blood sugar management:

• Glucose-dependent insulin stimulation (low hypoglycemia risk compared to sulfonylureas or insulin)
• Slowed gastric emptying reduces postprandial glucose spikes
• Weight loss (which itself improves insulin sensitivity)
• Reduction in hepatic glucose production

The SUSTAIN and AWARD trial programs established the glucose-lowering efficacy. Tirzepatide’s SURPASS trials showed efficacy exceeding most other diabetes medications.

The Cardiovascular Evidence: Beyond Blood Sugar

This is the part of the GLP-1 story that deserves far more attention than it gets. These medications were shown to reduce major cardiovascular events (heart attack, stroke, cardiovascular death) in dedicated outcomes trials – an effect that appears to go beyond what blood sugar reduction alone would explain.

Key cardiovascular outcomes trials:

• LEADER trial (liraglutide): 13% reduction in major cardiovascular events, 15% reduction in cardiovascular mortality
• SUSTAIN-6 trial (semaglutide): 26% reduction in major cardiovascular events
• REWIND trial (dulaglutide): 12% reduction in major cardiovascular events
• SELECT trial (semaglutide in non-diabetic patients with obesity and cardiovascular disease, 2023): 20% reduction in cardiovascular events – the first major cardiovascular outcomes trial of a GLP-1 in people without diabetes

The SELECT trial result is particularly significant. It suggests the cardiovascular benefit may apply beyond the diabetic population to people with obesity and established cardiovascular disease – potentially expanding appropriate use considerably.

FDA approval expansion: Based on SELECT trial data, the FDA approved semaglutide (Wegovy) for cardiovascular risk reduction in adults with obesity and established cardiovascular disease in March 2024 – regardless of diabetes status.

The Weight Loss Data

The weight loss efficacy of these medications is genuinely unprecedented for a pharmacological intervention:

Semaglutide (Wegovy) – STEP trials:

• Average weight loss: approximately 15% of body weight over 68 weeks
• Approximately 35% of participants lost 20% or more of body weight
• Compare to previous best weight loss medications: phentermine/topiramate (9-10%), orlistat (3-5%)

Tirzepatide (Zepbound) – SURMOUNT trials:

• Average weight loss: approximately 20-22% of body weight at highest dose over 72 weeks
• Approximately 45% of participants lost 20% or more of body weight

These are not trivial numbers. 15-22% weight loss is in the range historically associated only with bariatric surgery. And the health benefits accompanying this degree of weight loss are meaningful: improvements in blood pressure, lipids, blood glucose, sleep apnea, joint pain, and quality of life.

The weight returns after stopping: In the STEP 4 withdrawal trial, patients who stopped semaglutide after 20 weeks of treatment regained approximately two-thirds of lost weight within the following 48 weeks. This is the defining characteristic of GLP-1 agents for weight management: they work while you take them, and their effects reverse when you stop. They treat obesity as the chronic condition it is – requiring ongoing management.

Who These Medications Are Approved For

For type 2 diabetes (semaglutide as Ozempic, tirzepatide as Mounjaro, and others):

• Adults with type 2 diabetes as an adjunct to diet and exercise
• Particularly beneficial in patients with established cardiovascular disease or high cardiovascular risk (where the mortality reduction is most clinically meaningful)
• ADA guidelines now recommend GLP-1 agonists as preferred agents in type 2 diabetes with established ASCVD, heart failure, or CKD (beyond just glucose lowering)

For chronic weight management (semaglutide as Wegovy, tirzepatide as Zepbound, liraglutide as Saxenda):

• Adults with BMI ≥30 (obesity)
• Adults with BMI ≥27 (overweight) plus at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
• As an adjunct to reduced calorie diet and increased physical activity

For cardiovascular risk reduction (semaglutide as Wegovy):

• Adults with established cardiovascular disease and BMI ≥27, regardless of diabetes status (based on SELECT trial data, FDA-approved March 2024)

Who they’re not approved for:

• People without diabetes, obesity, or cardiovascular disease who simply want to lose weight for aesthetic reasons
• Children under 12 (Wegovy approved 12+ for obesity in 2022; Saxenda approved 12+ for obesity)
• People with personal or family history of medullary thyroid carcinoma or MEN2 syndrome (black box warning for thyroid C-cell tumors based on rodent data – causal relationship in humans not established but warrants caution)

The Side Effect Reality

Gastrointestinal Side Effects

GI effects are the most common side effects and the most common reason for discontinuation:

• Nausea: Very common, particularly when starting or increasing dose (affects 40-50% at some point)
• Vomiting: Less common but significant
• Diarrhea: Common, particularly with higher doses
• Constipation: Also common, somewhat paradoxically alongside diarrhea
• GERD/reflux: Slowed gastric emptying worsens reflux symptoms

The slow dose escalation protocol (starting low and increasing every 4 weeks) is specifically designed to minimize GI side effects. Most side effects peak in the first weeks after each dose increase and improve with time. Taking with food and avoiding large meals helps.

Muscle Loss Concern

Weight loss with GLP-1 medications includes both fat mass and lean mass (muscle). Studies suggest approximately 25-40% of weight lost may be lean mass – comparable to or slightly higher than dietary restriction alone.

This is a clinically important concern, particularly in older adults where muscle preservation is critical. Mitigating strategies: adequate protein intake (1.2-1.6g/kg/day) and resistance exercise while on these medications. Research into combination with muscle-preserving interventions is ongoing.

Pancreatitis

GLP-1 medications carry a warning about pancreatitis. The causal relationship is not definitively established in clinical trials (the large cardiovascular outcomes trials didn’t show increased pancreatitis rates), but the warning exists and patients should stop the medication and seek care if they develop severe abdominal pain, particularly radiating to the back.

Relative contraindication in people with history of pancreatitis.

Thyroid Concerns

Rodent studies found GLP-1 receptor agonists cause C-cell thyroid tumors at high doses. This has not been demonstrated in humans in clinical trials, but medullary thyroid carcinoma and MEN2 syndrome remain contraindications.

“Ozempic Face”

The rapid loss of facial fat that accompanies significant weight loss from GLP-1 medications produces what’s been called “Ozempic face” – a gaunt, aged facial appearance from subcutaneous facial fat loss. This is a cosmetic consequence of rapid substantial weight loss rather than a direct drug effect, and it’s the same phenomenon seen with rapid weight loss by any means.

Gallstones

Significant weight loss by any mechanism increases gallstone risk (rapid fat mobilization changes bile composition). GLP-1-associated weight loss carries this same risk. Some studies show modestly higher gallbladder disease rates with GLP-1 medications.

The Access and Shortage Problem

The off-label prescribing of Ozempic for weight loss in people without diabetes created significant shortages of semaglutide, affecting diabetic patients who couldn’t access their prescribed medication. This remains an ongoing tension in the GLP-1 space – high demand for weight loss applications creating supply constraints for diabetic patients whose cardiovascular and metabolic outcomes depend on these medications.

Insurance coverage is the other major barrier: Wegovy and Zepbound are expensive ($900-1,300/month list price), and many insurance plans cover the diabetes indications (Ozempic, Mounjaro) but not the weight management approvals (Wegovy, Zepbound). The AHA, AACE, and other societies have advocated for broader insurance coverage of obesity pharmacotherapy given the cardiovascular outcome data.

Frequently Asked Questions

Is Ozempic the same as Wegovy? Same active ingredient (semaglutide), different approved doses and indications. Ozempic is approved for type 2 diabetes at up to 2mg weekly. Wegovy is approved for weight management at up to 2.4mg weekly. Using Ozempic off-label for weight loss in people without diabetes has contributed to drug shortages affecting diabetic patients.

Do I need to stay on these medications forever? For most people, yes – if weight loss or blood sugar control are the goals and the underlying condition (obesity, diabetes) is ongoing. The STEP 4 withdrawal trial showed weight rapidly returns after stopping. This is the nature of treating a chronic condition – not a unique property of these medications compared to hypertension or cholesterol medications.

Are compounded semaglutide versions safe? Compounded versions of semaglutide (produced by compounding pharmacies during shortages) are not FDA-approved, not held to the same manufacturing standards, and carry unknown efficacy and safety profiles. The FDA has flagged concerns about impurities and incorrect dosing from compounded GLP-1 products. The FDA has stated that the branded shortage status (which permitted compounding) has ended for semaglutide; compounding should no longer continue.

Can teenagers use these medications? Wegovy (semaglutide) received FDA approval for obesity treatment in adolescents aged 12 and older in 2022, based on the STEP TEENS trial showing significant weight reduction. Liraglutide (Saxenda) is also approved 12+. These are appropriate clinical tools in adolescents with obesity and health consequences – they’re not approved for cosmetic weight loss.

Will I lose muscle on these medications? Some lean mass loss accompanies the weight loss from GLP-1 medications. The proportion varies. Adequate protein intake (at least 1.2-1.5g/kg/day) and regular resistance exercise are the evidence-based strategies to minimize muscle loss while benefiting from fat loss. This is clinically important particularly for older adults and should be discussed with your prescribing doctor.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. GLP-1 medication prescribing, dosing, and monitoring should be directed by a qualified healthcare provider based on your complete medical history, current medications, and specific health goals. These medications have specific approved indications and contraindications that require medical assessment.

References

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine. 2016;375(4):311-322. https://doi.org/10.1056/NEJMoa1603827
2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563
4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
6. American Diabetes Association. Standards of medical care in diabetes – 2024. Diabetes Care. 2024;47(Suppl 1). https://doi.org/10.2337/dc24-S001
7. Food and Drug Administration (FDA). FDA approves new indication for Wegovy. March 2024. https://www.fda.gov/drugs/news-events-human-drugs
8. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8). JAMA. 2022;327(2):138-150. https://doi.org/10.1001/jama.2021.23619
9. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). GLP-1 receptor agonists for type 2 diabetes. https://www.niddk.nih.gov
10. Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3(3):153-165. https://doi.org/10.1016/j.cmet.2006.01.004